Stream Biomedical

Executive Summary

Stream Biomedical is a preclinical-stage biotechnology company developing LG3, a first-in-class biologic therapy designed to restore the brain's natural repair mechanisms following injury or disease. The company focuses on targeting neurovascular dysfunction as a central driver in conditions like Alzheimer's disease, stroke, and traumatic brain injury. Its approach aims to protect brain cells, repair the blood-brain barrier, and reactivate endogenous neurorepair pathways. Founded in 2018 and based in San Diego, Stream Biomedical is privately held and has not yet disclosed funding or valuation. The company's technology addresses significant unmet medical needs in neurovascular and neurodegenerative diseases, which represent large and growing markets. However, as a preclinical-stage entity with no disclosed pipeline or clinical data, the risk profile is high. The company's ability to advance LG3 into clinical trials and secure partnerships or funding will be critical for its future success.

Upcoming Catalysts (preview)

• Q4 2026IND-Enabling Studies Initiation40% success
• Q2 2026Series A or Seed Funding Round50% success
• Q3 2026Publication of Preclinical Data for LG360% success